Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpromazine plus standard Stupp regimen in newly diagnosed glioblastoma
2019-001988-75Phase 2Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Aminazin in glioblastoma (GBM), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Progression-Free Survival at 6 months (PFS-6). Started May 2021; status: completed.
02
Drugs
Aminazin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2019-001988-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001988-75.